Trial Number

012-20

Age range

30 years to 80 years

Gender

Male or Female

Enrolling Patients

Yes

Stroke is one of the top causes of death and major functional disability worldwide. Treatment options for acute ischemic stroke are limited and primarily focus on timely clot removal to restore circulation. A small proportion of patients are eligible for tissue plasminogen activator (tPA) and/or thrombectomy. However, treatment response is incomplete for many patients, and even patients who respond to treatment may have residual neurologic impairment.Elezanumab is an investigational product under development for improvement of neurologic function in patients with acute ischemic stroke. A novel treatment like elezanumab, with a potentially neurorestorative mechanism of action, may improve neurologic function, and represents a significant advance in available treatment options for patients suffering from acute ischemic stroke.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.